Bristol-Myers warns I-O blockbuster Opdivo will be 'under pressure' in 2020

Bristol-Myers Squibb's Opdivo had been riding high even amid intense competition, particularly from Merck & Co.'s fast-growing Keytruda. But the immuno-oncology med hit something of a wall in the third quarter, and execs are warning that it'll face a tough 2020.